Stryker Corporation
Stryker Corporation (SYK) is a global medical‑technology company best known for orthopaedics, surgical equipment, neurotechnology and patient-handling systems. Investors should know it sells high-margin implants, powered surgical tools and capital equipment to hospitals and clinics, giving it exposure to both recurring consumable sales and larger, cyclical procedure volumes. Growth drivers include an ageing population, innovation in implants and minimally invasive procedures, geographic expansion and selective acquisitions. Key considerations are sensitivity to elective-surgery cycles, hospital capital spending and regulatory approvals; reimbursement policies and competition from other device makers can also affect results. Stryker has a track record of reinvesting in R&D, pursuing M&A and returning cash to shareholders, but margins and growth rates can vary over time. This is general, educational information only — not personal investment advice. Values can rise and fall and past performance is not a reliable guide. Suitability depends on your circumstances; consider seeking regulated financial advice before investing.
Why It's Moving
Stryker Bolsters Investor Confidence with Dividend Hike and Insider Option Exercise Amid Healthcare Strength
- President and COO Spencer S. Stiles exercised 13,840 stock options at $96.64 on February 3, disposing of some shares but retaining a hefty holding, hinting at faith in long-term value.
- Company announced $0.88 quarterly dividend on February 4, boosting the annualized payout and reflecting solid financial health post-recent earnings beats.
- Recent stock stability around $360-369 highlights resilience in healthcare, fueled by prior revenue growth of 11.4% and analyst upgrades eyeing sustained medtech demand.
Stryker Bolsters Investor Confidence with Dividend Hike and Insider Option Exercise Amid Healthcare Strength
- President and COO Spencer S. Stiles exercised 13,840 stock options at $96.64 on February 3, disposing of some shares but retaining a hefty holding, hinting at faith in long-term value.
- Company announced $0.88 quarterly dividend on February 4, boosting the annualized payout and reflecting solid financial health post-recent earnings beats.
- Recent stock stability around $360-369 highlights resilience in healthcare, fueled by prior revenue growth of 11.4% and analyst upgrades eyeing sustained medtech demand.
When is the next earnings date for Stryker Corporation (SYK)?
Stryker's next earnings date is scheduled for April 30, 2026, covering Q1 2026 results. This follows the recent Q4 2025 report released on January 29, 2026, which beat expectations. Investors should monitor official channels for any updates to this schedule.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Stryker's stock, expecting it to rise significantly in value.
Financial Health
Stryker Corporation is showing strong profits and cash flow, indicating solid business performance.
Dividend
Stryker's dividend yield of 0.92% is low, making it less appealing for dividend-focused investors. If you invested $1000 you would be paid $9.20 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SYK
Healthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: October 14, 2025
Explore BasketHealthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: September 22, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Elective Surgery Exposure
Stryker benefits from demand for joint replacements and minimally invasive procedures, though revenues can move with surgical volumes and economic cycles.
Innovation and M&A
Regular new-product launches and selective acquisitions can extend market share, but integration and regulatory approval carry execution risk.
Global Footprint
Diversified geographic presence helps growth and resilience, though it brings exposure to local reimbursement policies and currency fluctuations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
DexCom, Inc.
Manufactures and distributes medical device software for diabetes care
Neogen Corp
Neogen Corp is a food safety and animal safety diagnostics company that provides products and services to the food and animal feed industries.
UnitedHealth Group Incorporated
Provides healthcare services to individuals and organizations
